JP2004528307A - サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法 - Google Patents

サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法 Download PDF

Info

Publication number
JP2004528307A
JP2004528307A JP2002573009A JP2002573009A JP2004528307A JP 2004528307 A JP2004528307 A JP 2004528307A JP 2002573009 A JP2002573009 A JP 2002573009A JP 2002573009 A JP2002573009 A JP 2002573009A JP 2004528307 A JP2004528307 A JP 2004528307A
Authority
JP
Japan
Prior art keywords
keto
ketoalkanoic acid
ethyl pyruvate
mediated
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002573009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528307A5 (https=
Inventor
ミッチェル ピー． フィンク
ルイス ウリョア
ケビン ジェイ． トレーシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
North Shore Long Island Jewish Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Shore Long Island Jewish Research Institute filed Critical North Shore Long Island Jewish Research Institute
Publication of JP2004528307A publication Critical patent/JP2004528307A/ja
Publication of JP2004528307A5 publication Critical patent/JP2004528307A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2002573009A 2001-03-15 2002-03-15 サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法 Pending JP2004528307A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27627901P 2001-03-15 2001-03-15
PCT/US2002/008283 WO2002074301A1 (en) 2001-03-15 2002-03-15 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions

Publications (2)

Publication Number Publication Date
JP2004528307A true JP2004528307A (ja) 2004-09-16
JP2004528307A5 JP2004528307A5 (https=) 2005-12-22

Family

ID=23055992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002573009A Pending JP2004528307A (ja) 2001-03-15 2002-03-15 サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法

Country Status (6)

Country Link
US (2) US6943190B2 (https=)
EP (1) EP1379230A4 (https=)
JP (1) JP2004528307A (https=)
AU (1) AU2002255805B2 (https=)
CA (1) CA2440480A1 (https=)
WO (1) WO2002074301A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533433A (ja) * 2006-04-12 2009-09-17 アレクサンダー，ランヤ，エル． ピルビン酸アルキルエステルを含む組成物とその使用
JP2011105745A (ja) * 2002-12-06 2011-06-02 North Shore-Long Island Jewish Research Inst α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
JPWO2009116546A1 (ja) * 2008-03-18 2011-07-21 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
WO2002074301A1 (en) * 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
EP1377339A4 (en) * 2001-04-04 2006-05-31 Critical Therapeutics Inc PROCEDURE FOR PREVENTING AKUTER NIERENINSUFFIZIENZ
DE60228954D1 (en) 2001-05-03 2008-10-30 Galileo Lab Inc Pyruvatderivate
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US7122578B2 (en) * 2001-09-11 2006-10-17 Alain Martin Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
AU2003228099A1 (en) * 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2528144A1 (en) * 2003-06-09 2005-01-20 Mitchell P. Fink Method for treating acute pancreatitis
WO2005002563A2 (en) * 2003-06-13 2005-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Eduction Method for treating alcoholic hepatitis
ES2222093A1 (es) 2003-07-01 2005-01-16 Advanced In Vitro Cell Technologies, S.L. Metodo para el almacenamiento y/o transporte de cultivos celulares in vitro.
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
US20050095246A1 (en) * 2003-10-24 2005-05-05 Medtronic, Inc. Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
WO2006012373A2 (en) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
EP1874407B1 (en) 2005-04-15 2015-09-09 Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
US7754247B2 (en) * 2007-05-29 2010-07-13 University Of South Carolina Resuscitation fluid
US8211943B2 (en) * 2007-08-08 2012-07-03 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8114907B2 (en) * 2007-08-08 2012-02-14 Cellular Sciences Inc Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8815946B2 (en) * 2008-01-25 2014-08-26 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of proliferation and fibrotic response of activated corneal stromal cells
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
MX2011005207A (es) 2008-11-20 2011-07-20 Chata Biosystems Inc Alfa-ceto peracidos y metodos para producir y utilizar los mismos.
US8445717B2 (en) 2008-11-20 2013-05-21 Chd Bioscience, Inc. α-Keto alkylperacids and methods for producing and using the same
CA2750140C (en) 2008-12-30 2015-10-06 Hill's Pet Nutrition, Inc. Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
AU2010343129B2 (en) * 2009-12-29 2013-05-16 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
US11284621B2 (en) 2010-04-15 2022-03-29 Armis Biopharma, Inc. Compositions comprising peroxyacid and methods for producing and using the same
JP6291256B2 (ja) * 2011-02-17 2018-03-14 シーエイチディー・バイオサイエンス，インコーポレーテッド ペルオキシα−ケトカルボン酸を含む組成物、および該組成物を産生し、そして用いるための方法
US9044527B2 (en) 2011-02-17 2015-06-02 Chd Bioscience, Inc. Wound care products with peracid compositions
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
EP2908810A2 (en) 2012-10-18 2015-08-26 CHD Bioscience, Inc. Stable peracid-containing compositions
US9578879B1 (en) 2014-02-07 2017-02-28 Gojo Industries, Inc. Compositions and methods having improved efficacy against spores and other organisms
DE102017131059A1 (de) * 2017-12-22 2019-06-27 Christiane Kappert Physiologisch verträgliche Lösung mit einem Gehalt an Pyruvat und Glycin, eine Pyruvat und Glycin enthaltende Zusammensetzung und Verfahren zu deren Herstellung
EP3797766A1 (en) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions for use in reducing inflammation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2307075A (en) * 1940-08-02 1943-01-05 Carbide And Carbon Chemicais C Vinyl resin composition
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4246261A (en) * 1979-08-09 1981-01-20 Scott Eugene J Van Additives enhancing topical corticosteroid action
JPS5739260B2 (https=) * 1976-07-15 1982-08-20
JPH09512741A (ja) * 1994-05-04 1997-12-22 フォイト・ズルツァー・パピーアマシーネン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 紙塗被装置
JP2003510357A (ja) * 1999-10-07 2003-03-18 キサンタス ライフ サイエンシズ，インコーポレイテッド ピルビン酸エステル組成物ならびに虚血および再灌流の事象後の蘇生のための使用法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105782A (en) * 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
DE3133132A1 (de) * 1981-08-21 1983-03-03 Schweiger Hubert Terpene in synergistisch wirkenden kombinationen mit (alpha)-ketomono- und/oder (alpha)-ketodicarbonsaeuren und/oder deren mono- bzw. mono- und/oder diester und verwendung dieser pflanzlichen wirkstoffkombinationen als bioaktive mittel in arznei-, kosmetischen und dermatologischen mitteln
EP0215138B1 (fr) 1985-09-06 1991-01-16 Societe Des Produits Nestle S.A. Préservation des tissus vivants
US6051609A (en) 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
US5210098A (en) 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
AU8539491A (en) * 1990-09-21 1992-04-15 Regents Of The University Of Minnesota Pyruvate solutions to counteract acute renal failure
US5648380A (en) 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
WO1993006726A1 (en) 1991-09-30 1993-04-15 Mackenzie Walser Methods for treatment of free-radical-mediated tissue injury
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
US5480909A (en) 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5908611A (en) 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
AU719332B2 (en) * 1995-09-19 2000-05-04 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US6086789A (en) 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5756469A (en) 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US6417231B1 (en) * 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
JP4885362B2 (ja) 1999-05-14 2012-02-29 セルラー サイエンセズ インコーポレイテッド 炎症反応により生ずる哺乳動物の鼻および副鼻洞の病気を処置する方法および組成物
US6846842B2 (en) * 1999-10-07 2005-01-25 Beth Israel Deconess Medical Center, Inc. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
WO2002074301A1 (en) * 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2307075A (en) * 1940-08-02 1943-01-05 Carbide And Carbon Chemicais C Vinyl resin composition
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
JPS5739260B2 (https=) * 1976-07-15 1982-08-20
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4246261A (en) * 1979-08-09 1981-01-20 Scott Eugene J Van Additives enhancing topical corticosteroid action
JPH09512741A (ja) * 1994-05-04 1997-12-22 フォイト・ズルツァー・パピーアマシーネン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 紙塗被装置
JP2003510357A (ja) * 1999-10-07 2003-03-18 キサンタス ライフ サイエンシズ，インコーポレイテッド ピルビン酸エステル組成物ならびに虚血および再灌流の事象後の蘇生のための使用法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6008055131, ＣＲＥＳＴＡＮＥＬＬＯ，Ｊ．Ａ． ｅｔ ａｌ， Ｐｙｒｕｖａｔｅ ｉｍｐｒｏｖｅｓ ｍｙｏｃａｒｄｉａｌ ｔｏｌｅｒａｎｃｅ ｔｏ ｒｅｐｅｒｆｕｓｉｏｎ ｉｎｊｕｒｙ ｂｙ ａｃｔｉｎｇ ａｓ ａｎ *
JPN6008055132, ＤＥＢＯＥＲ，Ｌ．Ｗ． ｅｔ ａｌ， Ｐｙｒｕｖａｔｅ ｅｎｈａｎｃｅｓ ｒｅｃｏｖｅｒｙ ｏｆ ｒａｔ ｈｅａｒｔｓ ａｆｔｅｒ ｉｓｃｈｅｍｉａ ａｎｄ ｒｅｐｅｒｆｕｓｉｏｎ ｂｙ ｐｒｅｖｅｎ *
JPN6008055133, ＧＨＡＮＤＯＵＲ， ＭＡ ｅｔ ａｌ， Ｊ Ｉｎｄｉａｎ Ｃｈｅｍ Ｓｏｃ， １９８８， Ｖｏｌ．６５， Ｎｏ．１０， ｐ．７１６−８ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011105745A (ja) * 2002-12-06 2011-06-02 North Shore-Long Island Jewish Research Inst α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
JP2009533433A (ja) * 2006-04-12 2009-09-17 アレクサンダー，ランヤ，エル． ピルビン酸アルキルエステルを含む組成物とその使用
JPWO2009116546A1 (ja) * 2008-03-18 2011-07-21 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物

Also Published As

Publication number Publication date
US6943190B2 (en) 2005-09-13
EP1379230A1 (en) 2004-01-14
US20050245609A1 (en) 2005-11-03
CA2440480A1 (en) 2002-09-26
WO2002074301A1 (en) 2002-09-26
EP1379230A4 (en) 2009-01-21
US20040110833A1 (en) 2004-06-10
AU2002255805B2 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
JP2004528307A (ja) サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法
AU2002255805A1 (en) Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
AU2021200117A1 (en) Diacerein or its analogs for inhibiting expression of ASC, NLRP3, and/or formation of NLRP3 inflammasome complex
PT1112075E (pt) Composições para o tratamento da disfunção eréctil masculina
CA2440744C (en) Il-12 expression controlling agent
AU2015217293A1 (en) Compositions and methods for treating diabetes and liver diseases
WO2016163082A1 (ja) Ａｌａ類を含むウイルス感染症予防／治療剤
EP4313067A1 (en) Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof
WO2012062676A1 (de) Lisurid, tergurid und derivate davon zur verwendung in der prophylaxe und/oder therapie fibrotischer veränderungen
ZA200105275B (en) New use of melagatran.
JP2008526953A (ja) 炎症性疾患のプラジカンテルでの治療
KR20240035919A (ko) 신규한 글루타미닐 고리화효소 억제제 및 다양한 질환의 치료에서의 이의 용도
TW200306853A (en) Therapeutic agent for glomerular disease
CA2124912A1 (en) Therapeutic composition
RU2275906C2 (ru) Средство для лечения болезни паркинсона, включающее в качестве активного ингредиента соединение, улучшающее астроцитную функцию
US20200188379A1 (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
JP2753972B2 (ja) インポテンツの治療
AU2011223945B2 (en) Compositions and methods for treating viral diseases
WO2022170396A1 (en) Agents and methods for therapy and prophylaxis
JP2007055900A (ja) 炎症性疾患の治療及び予防用医薬組成物
JPH08259440A (ja) 急性尿閉治療用脱アセチル化モキシシライト
KR20190035724A (ko) N,n-비스-2-메르캅토에틸 이소프탈아미드의 용도
JP2022528481A (ja) ピモジドとメトトレキサートの医薬組成物、及びその使用
US11819508B2 (en) Miltefosine for the treatment of viral infections including covid-19
CA3214549A1 (en) Nitazoxanide in the treatment of sepsis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090327

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100607